Management of Coronavirus Disease 2019 Patients With Lung Cancer: Experience From a Thoracic Oncology Center.
COVID-19
clinical management
infection
lung cancer
thoracic oncology
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
12
2020
accepted:
11
03
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Cancer patients appear to be at a higher risk of complications from coronavirus disease 2019 (COVID-19). Specific data related to lung cancer (LC) patient management, active treatment, and/or recent diagnosis are still very limited. Here, we aimed to investigate the clinical presentation, baseline features, and clinical outcomes of LC patients with COVID-19. A retrospective case study was performed at Centro Hospitalar Universitário de São Joao, a tertiary hospital in the North of Portugal. Data from LC patients diagnosed with COVID-19 were collected during the first 10 months of the COVID-19 pandemic (March 2020-January 2021). Twenty-eight patients with active LC were diagnosed with COVID-19, being adenocarcinoma the most common histological type present ( This is one of the first studies reporting the adverse outcomes associated with COVID-19 in LC patients at same time that adds evidence regarding the need to create protocols and guidelines to reduce the infection risk in such patients.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer patients appear to be at a higher risk of complications from coronavirus disease 2019 (COVID-19). Specific data related to lung cancer (LC) patient management, active treatment, and/or recent diagnosis are still very limited. Here, we aimed to investigate the clinical presentation, baseline features, and clinical outcomes of LC patients with COVID-19.
METHODS
METHODS
A retrospective case study was performed at Centro Hospitalar Universitário de São Joao, a tertiary hospital in the North of Portugal. Data from LC patients diagnosed with COVID-19 were collected during the first 10 months of the COVID-19 pandemic (March 2020-January 2021).
RESULTS
RESULTS
Twenty-eight patients with active LC were diagnosed with COVID-19, being adenocarcinoma the most common histological type present (
CONCLUSION
CONCLUSIONS
This is one of the first studies reporting the adverse outcomes associated with COVID-19 in LC patients at same time that adds evidence regarding the need to create protocols and guidelines to reduce the infection risk in such patients.
Identifiants
pubmed: 34368223
doi: 10.3389/fmolb.2021.639676
pmc: PMC8339998
doi:
Types de publication
Journal Article
Langues
eng
Pagination
639676Informations de copyright
Copyright © 2021 Coelho, Santos, Araújo, Bastos, Magalhães, Hespanhol, Queiroga, Cruz-Martins and Fernandes.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2020 Apr 22;10:665
pubmed: 32391282
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Oncol. 2020 Jul;31(7):832-834
pubmed: 32278879
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170